108 related articles for article (PubMed ID: 33546530)
1. Megakaryocytic Clustering in Chronic Myeloid Leukemia: Can it be a Predictor of Clinical Outcome?
Mughal Z; Babar H; Ashraf S; Hamid A; Khokhar A; Qamar S
J Coll Physicians Surg Pak; 2021 Jan; 31(1):34-38. PubMed ID: 33546530
[TBL] [Abstract][Full Text] [Related]
2. [Therapeutic Effect of Imatinib Made in Real World to Newly Diagnosed Chronic Myeloid Leukemia].
Ye YF; Lyu XM; Li HL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):456-461. PubMed ID: 33812415
[TBL] [Abstract][Full Text] [Related]
3. Factors Affecting Early Molecular Response in Chronic Myeloid Leukemia.
Chikkodi SV; Malhotra P; Naseem S; Khadwal A; Prakash G; Sahu KK; Kumari S; Suri V; Varma N; Varma S
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S114-9. PubMed ID: 26297263
[TBL] [Abstract][Full Text] [Related]
4. Megakaryocytes carry the fused bcr-abl gene in chronic myeloid leukaemia: a fluorescence in situ hybridization analysis from bone marrow biopsies.
Nolte M; Werner M; Ewig M; von Wasielewski R; Link H; Diedrich H; Georgii A
Virchows Arch; 1996 Mar; 427(6):561-5. PubMed ID: 8605566
[TBL] [Abstract][Full Text] [Related]
5. EUTOS CML prognostic scoring system predicts ELN-based 'event-free survival' better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate.
Uz B; Buyukasik Y; Atay H; Kelkitli E; Turgut M; Bektas O; Eliacik E; Isik A; Aksu S; Goker H; Sayinalp N; Ozcebe OI; Haznedaroglu IC
Hematology; 2013 Sep; 18(5):247-52. PubMed ID: 23540886
[TBL] [Abstract][Full Text] [Related]
6. Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.
Faye BF; Dieng N; Seck M; Gadji M; Gueye YB; Sy D; Toure SA; Sall A; Toure AO; Dieye TN; Diop S
Ann Hematol; 2016 Oct; 95(10):1603-10. PubMed ID: 27370991
[TBL] [Abstract][Full Text] [Related]
7. Chronic phase chronic myeloid leukemia: response of imatinib mesylate and significance of Sokal score, age and disease duration in predicting the hematological and cytogenetic response.
Usman M; Syed NN; Kakepoto GN; Adil SN; Khurshid M
J Assoc Physicians India; 2007 Feb; 55():103-7. PubMed ID: 17571738
[TBL] [Abstract][Full Text] [Related]
8. The predictive value of early molecular response in chronic myeloid leukaemia patients treated with imatinib in a single real-world medical centre in a developing country.
Bee PC; Sekaran V; Ng RR; Kweh TY; Gan GG
Singapore Med J; 2017 Mar; 58(3):150-154. PubMed ID: 27029807
[TBL] [Abstract][Full Text] [Related]
9. CML with Megakaryocytic Blast Crisis: Report of 3 Cases.
Khemka R; Gupta M; Jena NK
Pathol Oncol Res; 2019 Jul; 25(3):1253-1258. PubMed ID: 30357754
[TBL] [Abstract][Full Text] [Related]
10. Morphological effects of imatinib mesylate (STI571) on the bone marrow and blood of patients with Philadelphia chromosome (Ph) positive chronic myeloid leukaemia.
McNamara C; Grigg A; Szer J; Roberts A; Campbell L; Hoyt R; Lynch K; Juneja S
Clin Lab Haematol; 2003 Apr; 25(2):119-25. PubMed ID: 12641616
[TBL] [Abstract][Full Text] [Related]
11. [Values of Different Prognostical Score Systems in Evaluation of Clinical Efficacy for Patients with Newly Diagnosed Chronic Myeloid Leukemia].
Wang PP; Zhang PP; Zhang J; Xi YM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Jun; 27(3):723-728. PubMed ID: 31204922
[TBL] [Abstract][Full Text] [Related]
12. Profile of BCR-ABL transcript levels based on Sokal prognostic score in chronic myeloid leukemia patients treated with imatinib.
Ashariati A; Ugroseno S
Acta Med Indones; 2013 Apr; 45(2):107-13. PubMed ID: 23770790
[TBL] [Abstract][Full Text] [Related]
13. Marrow fibrosis is an independent predictor of hematological toxicity of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Ni J; Hong J; Zhang Z; Li Q; Xia R; Zeng Q; Sun G
Leuk Lymphoma; 2020 May; 61(5):1195-1200. PubMed ID: 31858854
[TBL] [Abstract][Full Text] [Related]
14. Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.
Frater JL; Tallman MS; Variakojis D; Druker BJ; Resta D; Riley MB; Hrisinko MA; Peterson LC
Am J Clin Pathol; 2003 Jun; 119(6):833-41. PubMed ID: 12817431
[TBL] [Abstract][Full Text] [Related]
15. Chronic myelogenous leukaemia (CML): an update.
Kumar L
Natl Med J India; 2006; 19(5):255-63. PubMed ID: 17203680
[TBL] [Abstract][Full Text] [Related]
16. Planned Pregnancy in Female Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy.
Dou X; Qin Y; Huang X; Jiang Q
Oncologist; 2019 Nov; 24(11):e1141-e1147. PubMed ID: 31186377
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy and safety of imatinib in treatment of 151 chronic myeloid leukemia patients].
Zhou L; Wang AH; Wang L; You JH; Li JM; Shen ZX
Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):13-7. PubMed ID: 18512309
[TBL] [Abstract][Full Text] [Related]
18. Bone marrow trephine biopsy findings in chronic myeloid leukemia.
Khonglah Y; Basu D; Dutta TK
Malays J Pathol; 2002 Jun; 24(1):37-43. PubMed ID: 16329554
[TBL] [Abstract][Full Text] [Related]
19. Performance of Sokal and Eutos Scores for Predicting Cytogenetic and Molecular Response in Newly Diagnosed Chronic Myeloid Leukemia-Chronic Phase Patients on Imatinib.
Ganguly S; Lakshmaiah KC; Jacob LA; Babu S; Dasappa L; Govind Babu KS
Indian J Hematol Blood Transfus; 2017 Mar; 33(1):82-86. PubMed ID: 28194061
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of efficacy and related factors in 85 chronic myeloid leukemia patients treated with imatinib mesylate].
Zhou KS; Wang YY; Zhao YZ; Yi SH; Qian LS; Wang GR; Yu Z; Wang Y; Wang JX; Qiu LG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):208-12. PubMed ID: 20137149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
